Recipharm Acquires Flamel Technologies Facility in Strategic Partnership Deal
Swedish CDMO, Recipharm AB, has entered into a long-term collaboration with Flamel Technologies SA, a drug-delivery company based in France. Under the terms of the agreement, Recipharm will acquire Flamel?s development and manufacturing facility located in Pessac, France, for EUR10.6 million plus the value of the inventory.
Swedish CDMO, Recipharm AB, has entered into a long-term collaboration with Flamel Technologies SA, a drug-delivery company based in France. Under the terms of the agreement, Recipharm will acquire Flamel’s development and manufacturing facility located in Pessac, France, for EUR10.6 million plus the value of the inventory. This strategic partnership will enable Recipharm to expand its services in France and increase the scale of its European reach.
Recipharm will incorporate Flamel’s drug-delivery technologies, which include the addition of new spray granulation and spray coating capabilities into its portfolio of offerings.
According to the press release, Recipharm will also separately make an investment of €10.5m in newly issued Flamel Shares, which corresponds to approximately 2.3% of Flamel shares.
Flamel will still have access to its development and manufacturing capabilities in Pessac. The French company will also be able to potentially use any of Recipharm’s other facilities for the development and manufacture of its proprietary pipeline. Recipharm has an option to negotiate with Flamel for the European rights to any product that Flamel plans to license for sale in the European market.
The deal is expected to close at the end of 2014.
Source: Recipharm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
